stockrowIllumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
Follow ILMN
Alert me
Illumina, Inc. (ILMN) Net income
Illumina, Inc.'s net income for fiscal 2025 was $850.0M, compared with −$1.2B in fiscal 2024. Over the twelve months to 30 September 2026 it was $895.0M. Over the past ten years it has ranged from −$4.4B (fiscal 2022) to $990.0M (fiscal 2019); the current reading is higher than 91% of that period. Illumina, Inc. ranks 9th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $850.0M | — |
| FY2024 | −$1.2B | — |
| FY2023 | −$1.2B | — |
| FY2022 | −$4.4B | — |
| FY2021 | $762.0M | 16.16% |
| FY2020 | $656.0M | (33.74%) |
| FY2019 | $990.0M | 26.60% |
| FY2018 | $782.0M | 15.34% |
| FY2017 | $678.0M | 58.41% |
| FY2016 | $428.0M | (6.55%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $221.0M | 7.28% |
| Jun 2026 | $206.0M | 53.73% |
| Mar 2026 | $134.0M | (59.88%) |
| Dec 2025 | $334.0M | 122.67% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. compare | $1.4B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. | $895.0M |
| WAT Waters Corporation compare | $98.2M |
| GH Guardant Health, Inc. compare | −$485.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ILMN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement